September 12, 2016 09:23 AM EDT
R&D

Geron shares plunge as J&J as­sess­es an­oth­er set­back for ime­tel­stat

John Carroll

Editor & Founder

Geron man­aged to sore­ly dis­ap­point in­vestors this morn­ing, watch­ing its share price $GERN plunge 27% af­ter in­ves­ti­ga­tors at J&J cut loose a low dose of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times